Eli Lilly and Company today announced that Kimberly Blackwell, M.D., one of the nation’s leading breast cancer researchers, will join Lilly Oncology as vice president of early phase development and immuno-oncology on March 12, 2018.
Dr. Blackwell is currently professor of medicine and assistant professor of radiation oncology at Duke University Medical Center. She also serves as the co-director of the Duke women’s cancer program, associate director for strategic relations for the Duke Cancer Institute, research scholar for Susan G. Komen, and senior strategist for the Duke Innovation and Entrepreneurship Program. She will report to Levi Garraway, M.D., Ph.D., senior vice president, Global Development & Medical Affairs of Lilly Oncology.
“We are pleased and honored to welcome Dr. Blackwell to Lilly,” said Sue Mahony, Ph.D., senior vice president and president of Lilly Oncology. “She is highly regarded for her leadership in cancer research, especially metastatic breast cancer, where she has led programs that resulted in numerous groundbreaking regulatory approvals in the oncology sector.”
“Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop and advance novel treatments for people living with cancer.”
Source: Eli Lilly and Company
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
